Bevacizumab combined with chemotherapy and anti-PD-1 therapy for the first-line treatment of previously untreated metastatic triple-negative breast cancer

Saved in:
Bibliographic Details
Main Author: Bi-Cheng Wang
Format: Article
Language:English
Published: BMJ Publishing Group 2025-04-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/13/4/e012312.full
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850198622568710144
author Bi-Cheng Wang
author_facet Bi-Cheng Wang
author_sort Bi-Cheng Wang
collection DOAJ
format Article
id doaj-art-f785f80f09874ea99c086f26fef8bd2f
institution OA Journals
issn 2051-1426
language English
publishDate 2025-04-01
publisher BMJ Publishing Group
record_format Article
series Journal for ImmunoTherapy of Cancer
spelling doaj-art-f785f80f09874ea99c086f26fef8bd2f2025-08-20T02:12:49ZengBMJ Publishing GroupJournal for ImmunoTherapy of Cancer2051-14262025-04-0113410.1136/jitc-2025-012312Bevacizumab combined with chemotherapy and anti-PD-1 therapy for the first-line treatment of previously untreated metastatic triple-negative breast cancerBi-Cheng Wang0Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Chinahttps://jitc.bmj.com/content/13/4/e012312.full
spellingShingle Bi-Cheng Wang
Bevacizumab combined with chemotherapy and anti-PD-1 therapy for the first-line treatment of previously untreated metastatic triple-negative breast cancer
Journal for ImmunoTherapy of Cancer
title Bevacizumab combined with chemotherapy and anti-PD-1 therapy for the first-line treatment of previously untreated metastatic triple-negative breast cancer
title_full Bevacizumab combined with chemotherapy and anti-PD-1 therapy for the first-line treatment of previously untreated metastatic triple-negative breast cancer
title_fullStr Bevacizumab combined with chemotherapy and anti-PD-1 therapy for the first-line treatment of previously untreated metastatic triple-negative breast cancer
title_full_unstemmed Bevacizumab combined with chemotherapy and anti-PD-1 therapy for the first-line treatment of previously untreated metastatic triple-negative breast cancer
title_short Bevacizumab combined with chemotherapy and anti-PD-1 therapy for the first-line treatment of previously untreated metastatic triple-negative breast cancer
title_sort bevacizumab combined with chemotherapy and anti pd 1 therapy for the first line treatment of previously untreated metastatic triple negative breast cancer
url https://jitc.bmj.com/content/13/4/e012312.full
work_keys_str_mv AT bichengwang bevacizumabcombinedwithchemotherapyandantipd1therapyforthefirstlinetreatmentofpreviouslyuntreatedmetastatictriplenegativebreastcancer